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Parkinson’s disease (PD) presents with extensive heterogeneity in symptomatology, inviting examination of disease subtypes. One
significant categorization is by whether patients present at onset with tremor as the dominant symptom (TD) or with nontremor
symptoms (NTD). We examined differences in quality of life between TD and NTD patients using the Parkinson’s Disease
Questionnaire-39 (PDQ-39), correlating performance with aspects ofmotor function as indexed by theUnified Parkinson’s Disease
Rating Scale (UPDRS). Participants included 35 nondemented individuals (19 TD, 16 NTD) matched on clinical and demographic
characteristics. NTD had significantly lower overall PDQ-39 scores, particularly for the mobility subscale. Several UPDRS subscale
scores significantly correlated with quality of life, especially for NTD. Further, the correlations were driven by nontremor type
symptoms, even in TD patients. Determining reliable subtypes of PD may aid in prognosis and treatment optimization, thereby
enhancing quality of life in afflicted individuals.
1. Introduction
Parkinson’s disease (PD) is a degenerative disorder of the
central nervous system that demonstrates extensive het-
erogeneity in symptomatology, leading many investigators
to examine disease subtypes [1]. Researchers have used
predominance of specific motor symptoms, age of disease
onset, laterality of symptoms, disease severity, cognitive
performance, and several other categories to define subtypes
of PD [2].
The classification of initial symptom has been a major
focus of recent research. Individuals displaying primarily
rigidity and gait and balance symptoms (nontremor dom-
inant; NTD) and those with mainly tremor symptoms
(tremor dominant; TD) at diagnosis present differences in
clinical and cognitive profile [1–5]. In addition to exhibiting
more severe cardinal motor deficits including problems
with gait and balance, NTD individuals have been shown
to have increased levels of axial motor symptoms such as
freezing, falls, and difficulty with speech and swallowing,
as well as nonmotor symptoms such as poorer cognitive
functioning (particularly executive deficits) and increased
levels of depression [1–3, 5]. NTD individuals have also been
shown to be more likely to experience early onset dementia
than patients with TD [1].
Clinical differences found between TD and NTD may be
related to distinct neuropathological profiles that contribute
to tremor or nontremor symptoms. While tremor may
implicate pathology in the cortico-striato-thalamocortical
circuits caused by progressive dopamine depletion in the
substantia nigra, the presence of both axial motor symptoms
and nonmotor symptoms may reflect more extensive pathol-
ogy in additional cortical and subcortical brain regions. A
recent pathological analysis demonstrated that NTD cases
had significantly wider Lewy body distribution and increased
density in the substantia nigra, frontal, and transentorhinal
regions than did TD cases. NTD patients also showed
significantly more Alzheimer-like neurofibrillary pathology
and increased plaque formation in the neocortex as well as
more frequent amyloid angiopathy [1].
Motor subtypes may be relevant to understanding spe-
cific factors that may contribute to a patient’s quality of life,
thereby providing additional targets for PD treatments and
interventions [5]. The Parkinson’s Disease Questionnaire-39
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(PDQ-39) is a widely used self-report measure that includes
subscales measuring mobility, activities of daily living, emo-
tional well-being, stigma, social support, communication,
cognition, and bodily discomfort [6]. Factors that have been
shown to affect quality of life in PD include depression,
anxiety, cognitive functioning, motor symptom severity, and
the presence of additional axial motor symptoms [4, 7, 8].
One study found that patients with the akinetic-rigid
disease type of PD endorsed more negative symptoms on the
PDQ-39 than did individuals with the TD disease type [9].
A recent report found differences in activities of daily living
and quality of life between TD and NTD individuals even
prior to their diagnosis of PD [10]. Specifically, this study
found that individuals in the NTD group had significant
limitations in activities of daily living and a more negative
quality of life at their initial neurologist visit prior to
any dopaminergic treatment. Even at this first visit to the
neurologist, individuals in the NTD group had significantly
higher scores on the Unified Parkinson’s Disease Rating
Scale (UPDRS) and higher Hoehn and Yahr staging than
individuals in the TD group. Questions remain as to the
specific differences in quality of life for subgroups of PD
independent of motor symptom severity and stage of disease.
TheMotor Examination (Part III) of theUPDRS includes
26 items with scores ranging from 0 (absent or normal) to
4 (more severe impairment) [11]. Responses on the UPDRS
Motor Examination load onto six motor symptom domains
including tremor, rigidity, bradykinesia, facial expression,
speech, and axial impairments [12]. The six motor domains
can also be grouped into two subscales that represent pre-
dominantly dopaminergic or nondopaminergic symptoms
based on levodopa responsiveness [12]. The dopamine-
deficiency (DA) subscale includes the tremor, rigidity,
bradykinesia, and facial expression subscale scores, while
the nondopamine deficiency (non-DA) subscale includes the
speech and axial symptom subscale scores [12].
To the best of our knowledge, no studies to date have
directly examined the relation between the UPDRS and its
subscales with the subscales of the PDQ-39. This comparison
could elucidate the specific symptoms that most directly
contribute to a negative quality of life in individuals with PD,
which is important for designing themost effective treatment
plans. Because of the primacy of poorer quality of life in NTD
relative to TD patients, the present study aimed to examine
differences in quality of life in these subtypes using the PDQ-
39 and additionally to examine the associations between the
subscales of the PDQ-39 and the subscales of the UPDRS
motor examination.
2. Methods
2.1. Participants. Thirty-five nondemented patients with PD
(22 men, 13 women) were recruited from the outpatient
MovementDisorders Clinic of the Department of Neurology,
Boston Medical Center. The study was approved by the
Boston University Institutional Review Board, and all par-
ticipants provided informed consent. On the modified Mini-
Mental State Examination (mMMSE) [13], a cutoff score of
25 was used for PD participants as this form of the MMSE
is particularly sensitive to specific cognitive deficits found
in PD without dementia (scores converted from the 57-
point scale). This version of the MMSE includes additional
executive functioning components, such as forward and
backward digit span, as well as additional construction items.
Individuals with a history of substance abuse, head injury,
or neurologic disorders besides PD were excluded. None met
criteria for Dementia with Lewy Bodies as per McKeith [14].
Medication information was obtained for all partici-
pants. Levodopa equivalent dosages (LED) were calculated
based on previous reports with LED: (regular levodopa
dose × 1) + (levodopa controlled-release dose × 0.75) +
(pramipexole dose × 67.0) + (ropinirole dose × 16.67) +
(rotigotine × 16.67) + (pergolide dose and cabergoline
dose × 67.0) + (bromocriptine dose × 10) + ([regular
levodopa dose + levodopa controlled-release dose × 0.75) ×
0.25]) if taking tolcapone or entacapone [15].
2.2. Self-Report Measures. Motor symptom severity was
quantified using the UPDRS and Hoehn and Yahr stage
[16]. Information on type of motor symptom at onset
was obtained through patient report and confirmed when
possible by neurologist review. Based on the response to
the UPDRS question addressing the first PD symptom
experienced, subjects were categorized as either TD (tremor
dominant, n = 16) or NTD (nontremor dominant, n = 19).
Mood was assessed using the Beck Depression Inventory
(BDI-2) [17] and Beck Anxiety Inventory (BAI) [18]. All
patients received the PDQ-39 [6]. Higher scores on all
questionnaires indicate more severe symptoms.
2.3. Statistical Analysis. Independent samples t-tests were
used to compare demographic and clinical characteristics
of the subgroups. The Mann-Whitney U test was used to
compare TD and NTD individuals on the PDQ-39 and
its subscales. Spearman rank order correlations were used
to examine associations between subscales of the PDQ-39
and UPDRS for all the PD participants and for TD and
NTD patients separately. A P value of <.01 was considered
significant to control for multiple comparisons except for
subgroup analyses and where otherwise noted.
3. Results
3.1. Comparison of TD and NTD Patients on PDQ-39.
Demographic and clinical characteristics of TD and NTD
patients can be found in Table 1. TD and NTD individuals
did not significantly differ on age, UPDRS total, disease
duration, side of onset, male:female ratio, BAI, BDI, LED,
or MMSE score. Groups differed significantly on years of
education, with NTD individuals having significantly more
years of education (P < .05). Education was accordingly
included as a covariate in subsequent group analyses but did
not alter any of the findings.
Total PDQ-39 score was significantly higher for NTD
individuals than TD individuals (P < .03). A comparison of
the subscales of the PDQ-39 indicated that NTD individuals
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Table 1: Participant characteristics.
Age Female : male
Education,
years
UPDRS,
total
Duration of
Illness, years
H and Y
Stage†
MMSE BDI BAI
NTD
(n = 19)
64.0 (8.7) 7 : 12 17.7 (2.5)∗ 23.2 (9.1) 8.0 (4.3) 2 (2) 27.9 (1.2) 9.0 (4.3) 9.4 (5.9)
TD
(n = 16)
68.7 (6.2) 6 : 10 15.8 (1.9) 27.4 (9.4) 9.8 (5.9) 1.5 (2) 27.8 (1.0) 7.5 (5.2) 6.9 (3.2)
NTD: nontremor dominant; TD: tremor dominant; UPDRS: Unified Parkinson’s Disease Rating Scale; MMSE: Mini-Mental State Exam; H and Y: Hoehn and
Yahr; BDI: Beck Depression Inventory; BAI: Beck Anxiety Inventory. All values reported as means and standard deviations unless otherwise noted. ∗P < .05;
†median and range are reported.
Table 2: Significant correlations between PDQ-39 and UPDRS subscales for NTD and TD subjects.
UPDRS subscales
NTD TD
PDQ-39 subscales
ADL Communication Cognition Communication
Rigidity 0.67∗ NS NS 0.74∗∗
Bradykinesia 0.67∗∗ 0.59∗∗ NS NS
Speech 0.54∗ NS NS NS
DA-dependent 0.69∗∗ 0.61∗∗ NS NS
Facial expression NS 0.66∗∗ NS NS
Axial NS NS 0.59∗ NS
∗∗
P < .01,
∗P < .02.
0
10
20
30
40
50
60
70
NTD
TD
To
ta
l
sc
or
e
M
ob
ili
ty
A
D
L
St
ig
m
a
So
ci
al
su
pp
or
t
C
og
n
it
io
n
C
om
m
u
n
ic
at
io
n
B
od
ily
di
sc
om
fo
rt
E
m
ot
io
n
al
w
el
l-
be
in
g
∗
∗∗
Figure 1: Mean subscale scores on the PDQ-39 for NTD and TD
participants; ∗∗P < .01, ∗P < .05.
had significantly higher scores for the PDQ-39 mobility
subscale than TD individuals (P < .01), as shown in Figure 1.
There were no significant differences between groups for the
remaining subscales of the PDQ-39.
3.2. Correlations between Scores on PDQ-39 and UPDRS.
Performance on several subscales of the UPDRS was signif-
icantly correlated with scores on the PDQ-39 subscales. In
the entire PD group, scores on the Activities of Daily Living
(ADL) subscale of the PDQ-39 correlated significantly with
those of both the Rigidity (r = .40, P < .01) and Dopamine-
(DA-) dependent subscales of the UPDRS (r = .44, P <
.01). Scores on the Communication subscale of the PDQ-
39 correlated significantly with those of both the Rigidity
(r = .53, P < .01) and Facial Expression subscales of the
UPDRS (r = .47, P < .01).
When correlations were conducted for TD and NTD
patients separately, a different pattern of results emerged for
the two groups. For NTD individuals, scores on the ADL
subscale of the PDQ-39 correlated significantly with those
on the Rigidity (r = .67, P < .02), Bradykinesia (r = .67,
P < .01), Speech (r = .54, P < .02), and DA subscales
of the UPDRS (r = .69, P < .01). Additionally, scores
on the Communication subscale of the PDQ-39 correlated
significantly with those on the Bradykinesia (r = .59,
P < .01), Facial Expression (r = .66, P < .01), and
DA subscales of the UPDRS (r = .61, P < .01). For
TD individuals, scores on the Cognition subscale of the
PDQ-39 correlated significantly with those on the Axial
subscale of the UPDRS (r = .59, P < .02), and scores
on the Communication subscale of the PDQ-39 correlated
significantly with those on the Rigidity subscale of the
UPDRS (r = .74, P < .01). These results are summarized
in Table 2. NTD individuals showed a greater number of
significant correlations between subscales of the UPDRS and
subscales of the PDQ-39 than did TD individuals. Addition-
ally, scores on the subscales of the UPDRS that correlated
with scores on the PDQ-39 were primarily those corre-
sponding to nontremor symptoms in both NTD and TD
individuals.
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4. Discussion
We found that individuals with PD who experienced non-
tremor symptoms such as rigidity and gait and balance
impairments at diagnosis reported a significantly worse
quality of life than individuals who experienced tremor as
their initial symptom. This finding was particularly signifi-
cant in the domain of issues relating to mobility. Although
performance on the mobility subscale alone was significantly
different in NTD and TD, NTD patients endorsed a worse
quality of life than TD patients on all domains except in
the domain of social support, and their overall PDQ score
indicated significantly worse self-perceived quality of life.
These results are in line with those from Hariz and
Forsgren, who found significant differences in PDQ-39
scores in individuals with the TD and NTD subtypes of
PD [10]. Specifically, in their study the subgroup with NTD
had significantly worse scores than the TD subgroup for
the mobility, ADL, Communication, and Bodily Discomfort
subscales as well as for total scores [10]. We found significant
differences between NTD and TD for the total PDQ-39 score
as well as for the mobility subscale score. Hariz and Forsgren
reported significant differences between the NTD and TD
subgroups for total UPDRS scores and Hoehn and Yahr
staging, with the NTD group exhibiting more severe deficits
than the TD subgroup [10]. The present study extended
these findings by showing that group differences in PDQ-
39 scores were independent of motor symptom severity or
stage of disease, as no significant differences were found
between NTD and TD individuals for scores on the UPDRS
examination or Hoehn and Yahr staging in our sample.
Our results also demonstrated that subscales derived
from a commonly used quality of life measure, the PDQ-
39, correlated significantly with subscales of the UPDRS. In
the entire PD group, scores on the Rigidity subscale of the
UPDRS were significantly correlated with those on both the
ADL and Communication subscales of the PDQ-39, whereas
scores on the Tremor subscale did not correlate significantly
with those on any PDQ-39 subscale. A separate analysis for
TD and NTD patients revealed that the correlations between
performance on the PDQ-39 and UPDRS were primarily
driven by nontremor symptoms even in TD patients. This
finding indicates that nontremor symptoms in general more
negatively impact quality of life, regardless of initial motor
symptom. The subscales of the UPDRS that pointed to
significant relations with the quality of life subscales of
the PDQ-39 for TD individuals were for axial symptoms
and symptoms of rigidity. That is, for both TD and NTD
individuals, nontremor type symptoms appear to negatively
impact multiple domains of their quality of life. These results
provide evidence that tremor as a singular symptommay not
significantly compromise quality of life, whereas symptoms
of rigidity and bradykinesia may act as more substantial
contributors to deficits in self-reported quality of life.
Our findings provide insight into how the common
motor symptoms of PD negatively affect specific aspects
of quality of life. For example, performance on the
Communication subscale of the PDQ-39 was significantly
related to performance on the Facial Expression subscale
of the UPDRS, suggesting that difficulties with displaying
facial expressions contribute to problems with communi-
cation for patients with PD. A recent study examining
the effectiveness of a randomized controlled rehabilitation
trial for PD used the PDQ-39 to evaluate improvements
in quality of life [19]. Patients demonstrated the greatest
improvements in the communication domain of the PDQ-39
[19]. This finding demonstrated that communicationmay be
significantly related to quality of life and can be particularly
receptive to rehabilitation techniques. Accordingly, health
care providers should focus on efforts to improve speech and
communication skills in individuals with PD. Understanding
the relation between specific symptoms of PD and quality
of life may inform intervention strategies in order to most
effectively improve life quality for individuals with PD.
Additionally, for the entire PD group, scores on the
ADL subscale of the PDQ-39 also correlated significantly
with Dopamine- (DA-) dependent subscales of the UPDRS,
which includes the tremor, rigidity, bradykinesia, and facial
expression subscale scores. The non-DA-dependent subscale
includes the speech and axial symptom subscale scores of
the UPDRS. This finding provides evidence that the physical
symptoms of PD may have a larger effect on self-reported
quality of life than axial symptoms. This correlation was
driven by the NTD patients, indicating that quality of life
is more affected by symptoms in NTD individuals rather
than individuals with a tremor-dominant symptoms at
diagnosis.
Poorer scores on the PDQ-39may reflect that individuals
with the NTD symptom profile (i.e., more rigidity, gait, and
balance problems) experience more extensive disease pathol-
ogy than TD individuals [1]. While the presence of a tremor
may indicate the dopamine depletion in the substantia
nigra that negatively affects cortico-striato-thalamocortical
circuits, the presence of nontremor symptoms may indicate
pathology in additional cortical and subcortical structures
of the brain, such as frontal regions and the transentorhinal
cortex [1]. Individuals with NTDmay have a wider distribu-
tion and greater density of Lewy bodies in the brain than TD
individuals, which may contribute to more frequent or more
severe nontremor symptoms that ultimately have a negative
effect on quality of life. These symptoms may not respond as
well to the dopaminergic treatments that have been shown
to significantly improve the quality of life in individuals with
PD [1].
In summary, the present study provides evidence that
individuals with nontremor initial symptoms of PD endorse
a more negative quality of life than individuals who experi-
ence tremor as the initial symptom, despite lack of differences
in disease duration or severity. A novel finding of this study
is the demonstration of significant correlations between
performance on specific subscales of quality of life and
specific motor symptom domains. These correlations were
driven by nontremor symptoms, even in individuals with
tremor as the initial symptom. Determining reliable subtypes
and specific motor symptom profiles of PD may aid in
prognosis and individualized treatment plans, as well as assist
researchers in advancing the understanding of the etiology of
PD.
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